| Identification | Back Directory | [Name]
PC 190723 | [CAS]
951120-33-5 | [Synonyms]
PC190723
3-((6-chlorothiazolo[5,4-b]pyridin-2-yl)Methoxy)-2,6-difluorobenzaMide
Benzamide, 3-[(6-chlorothiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluoro-
3-[(6-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide | [Molecular Formula]
C14H8ClF2N3O2S | [MDL Number]
MFCD18382114 | [MOL File]
951120-33-5.mol | [Molecular Weight]
355.75 |
| Chemical Properties | Back Directory | [Melting point ]
218 °C | [Boiling point ]
462.3±45.0 °C(Predicted) | [density ]
1.593±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.15±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
3-[(6-Chlorothiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide is a small molecule cell-cycle inhibitor and has been used as an antibacterial agent. 3-[(6-Chlorothiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide was found to inhibit bacterial cell division protein FtsZ. | [in vivo]
PC190723 (30 mg/kg; subcutaneous/intravenous injection; single dose) has antibacterial effect in a mouse model of S. aureusinfection[1]. | Animal Model: | S. aureus treated mice[1] | | Dosage: | 30 mg/kg | | Administration: | Subcutaneous/intravenous injection; Single dose | | Result: | Resulted in a 100% survival of mice inoculated intraperitoneally with a potentially lethal dose of S. aureus, as compared with a 0% survival for the group receiving no compound.
Produced dose-dependent efficacy for both routes of administration with ED50 were 7.3 and 10.2 mg/kg for S.C. and I.V. administration, respectively.
|
|
|
| Company Name: |
Matrix Scientific
|
| Tel: |
803 788-9494 All other calls |
| Website: |
www.matrixscientific.com |
|